An Overview of Mouse Models of Nonalcoholic Steatohepatitis: From Past to Present
The DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.
Abstract
Non‐alcoholic fatty liver disease (NAFLD) is the most common chronic liver disease in the Western world. It is associated with obesity and type 2 diabetes and represents a spectrum of histological abnormalities ranging from simple steatosis to non‐alcoholic steatohepatitis (NASH), which can further progress to fibrosis, cirrhosis, hepatocellular carcinoma (HCC), and liver failure. To gain insight into the pathogenesis and evaluate treatment options, mouse models of NAFLD/NASH are of utmost importance. There is a high phenotypical variety in the available mouse models, however, models that truly display the full spectrum of histopathological and metabolic features associated with human NASH are rare. In this review, we summarize the most important NAFLD/NASH mouse models that have been developed over the years and briefly highlight the pros and cons. Also, we illustrate the preclinical research in which these models have been used. © 2016 by John Wiley & Sons, Inc.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Pioglitazone, Vitamin E, or Placebo for Nonalcoholic Steatohepatitis
Sanyal, A. J., Chalasani, N., Kowdley, K. V., McCullough, A., Diehl, A. M., Bass, N. M., Neuschwander-Tetri, B. A., Lavine, J. E., Tonascia, J., Unalp, A., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0907929 · Cited by 3,327
Evolution of inflammation in nonalcoholic fatty liver disease: The multiple parallel hits hypothesis
Tilg, H., & Moschen, A. R. (2010) · Hepatology · doi:10.1002/hep.24001 · Cited by 2,548
Neuschwander‐Tetri, B. A. (2010) · Hepatology · doi:10.1002/hep.23719 · Cited by 1,077
Shimomura, I., Hammer, R. E., Richardson, J. A., Ikemoto, S., Bashmakov, Y., Goldstein, J. L., & Brown, M. S. (1998) · Genes & Development · doi:10.1101/gad.12.20.3182 · Cited by 790
The role of fructose in the pathogenesis of NAFLD and the metabolic syndrome
Lim, J. S., Mietus-Snyder, M., Valente, A., Schwarz, J.-M., & Lustig, R. H. (2010) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2010.41 · Cited by 771 · cited 2×
“…obesity, hypertension, hypertriglyceridemia, insulin resistance, Mouse Models of Nonalcoholic Steatohepatitis 190 Volume 6 Current Protocols in Mouse Biology pro-inflammatory responses, and the formation of reactive oxygen species (Kelley et al., 2004; Lim et al., 2010; Crescenzo et al., 2014).”
BackgroundMouse models in non‐alcoholic fatty liver disease and steatohepatitis research
Anstee, Q. M., & Goldin, R. D. (2006) · International Journal of Experimental Pathology · doi:10.1111/j.0959-9673.2006.00465.x · Cited by 714
Metformin in non-alcoholic steatohepatitis.
Marchesini, G., Bianchi, G., Tomassetti, S., Zoli, M., & Melchionda, N. (2001) · The Lancet · doi:10.1016/s0140-6736(01)06042-1 · Cited by 682
Ratziu, V., Giral, P., Jacqueminet, S., Charlotte, F., Hartemann–Heurtier, A., Serfaty, L., Podevin, P., Lacorte, J., Bernhardt, C., Bruckert, E., et al. (2008) · Gastroenterology · doi:10.1053/j.gastro.2008.03.078 · Cited by 625 · cited 1×
“Moreover, in line with results from NASH mouse models, metformin- and thiazolidinedione-induced decrease in serum transaminases, improved hepatic steatosis, and inflammation have also been demonstrated in clinical studies (Marchesini et al., 2001; Ratziu et al., 2008).”
ResultGariani, K., Menzies, K. J., Ryu, D., Wegner, C. J., Wang, X., Ropelle, E. R., Moullan, N., Zhang, H., Perino, A., Lemos, V., et al. (2016) · Hepatology · doi:10.1002/hep.28245 · Cited by 368
Fujii, M., Shibazaki, Y., Wakamatsu, K., Honda, Y., Kawauchi, Y., Suzuki, K., Arumugam, S., Watanabe, K., Ichida, T., Asakura, H., et al. (2013) · Medical Molecular Morphology · doi:10.1007/s00795-013-0016-1 · Cited by 355 · cited 19×
“Mainly, dietinduced HCC models take a long time to develop, while it is not straightforward to eliminate off-target side effects in chemical-induced HCC.”
BackgroundMethodInfluentialSahai, A., Malladi, P., Pan, X., Paul, R., Melin-Aldana, H., Green, R. M., & Whitington, P. F. (2004) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00199.2004 · Cited by 290 · cited 5×
“In general, the atherogenic HChCh diet enriched with fat can result in the histological features of NASH, but the systemic profile is not entirely comparable (Sanches et al., 2015).”
BackgroundInfluentialSweeney, G. (2002) · Cellular Signalling · doi:10.1016/s0898-6568(02)00006-2 · Cited by 271
Nonalcoholic steatohepatitis: a search for factual animal models
Sanches, S. C. L., Ramalho, L. N. Z., Augusto, M. J., da Silva, D. M., & Ramalho, F. S. (2015) · BioMed Research International · doi:10.1155/2015/574832 · Cited by 174
Arsov, T., Silva, D. G., O’Bryan, M. K., Sainsbury, A., Lee, N. J., Kennedy, C., Manji, S. S. M., Nelms, K., Liu, C., Vinuesa, C. G., et al. (2006) · Molecular Endocrinology · doi:10.1210/me.2005-0494 · Cited by 166 · cited 4×
“Fat aussie is an obese mouse strain with a truncating mutation (foz) in the Alström syndrome or Alms1 gene (Arsov et al., 2006).”
BackgroundInfluentialWada, T., Miyashita, Y., Sasaki, M., Aruga, Y., Nakamura, Y., Ishii, Y., Sasahara, M., Kanasaki, K., Kitada, M., Koya, D., et al. (2013) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00419.2013 · Cited by 79
Nakayama, H., Otabe, S., Ueno, T., Hirota, N., Yuan, X., Fukutani, T., Hashinaga, T., Wada, N., & Yamada, K. (2007) · Metabolism · doi:10.1016/j.metabol.2006.11.004 · Cited by 79
Metformin prevents liver tumorigenesis induced by high-fat diet in C57Bl/6 mice
Tajima, K., Nakamura, A., Shirakawa, J., Togashi, Y., Orime, K., Sato, K., Inoue, H., Kaji, M., Sakamoto, E., Ito, Y., et al. (2013) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00133.2013 · Cited by 59 · cited 1×
“Other publications also demonstrate the beneficial effect of metformin on liver fat accumulation, inflammation of the adipose tissue, and fibrosis in various NASH mouse models (Tajima et al., 2013; Woo et al., 2014).”
Background
Cited by
Animal Models of Nonalcoholic Fatty Liver Disease—A Starter’s Guide
Van Herck, M., Vonghia, L., & Francque, S. (2017) · Nutrients · doi:10.3390/nu9101072 · Cited by 392
Collagenase Nanoparticles Enhance the Penetration of Drugs into Pancreatic Tumors
Zinger, A., Koren, L., Adir, O., Poley, M., Alyan, M., Yaari, Z., Noor, N., Krinsky, N., Simon, A., Gibori, H., et al. (2019) · ACS Nano · doi:10.1021/acsnano.9b02395 · Cited by 323
Farrell, G., Schattenberg, J. M., Leclercq, I., Yeh, M. M., Goldin, R., Teoh, N., & Schuppan, D. (2019) · Hepatology · doi:10.1002/hep.30333 · Cited by 313
“geNetIc MoDelS Genetic models of NASH are summarized in Table 2 and described in detail in several reviews.(10,12,14,17-21) Voluntary overeating occurs in mice with single mutations of appetite-regulating genes, especially ob/ob (leptin-deficient), db/db (deficient leptin signaling), foz/foz (spontaneous mutations in…”
Human Multilineage 3D Spheroids as a Model of Liver Steatosis and Fibrosis
Pingitore, P., Sasidharan, K., Ekstrand, M., Prill, S., Lindén, D., & Romeo, S. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20071629 · Cited by 152
“To understand molecular mechanisms of NAFLD and to identify new drugs several in vitro models of fatty liver disease based on 2D cell culture and in vivo mouse models have been exploited [9,10].”
BackgroundIn Vitro and In Vivo Models of Non-Alcoholic Fatty Liver Disease: A Critical Appraisal
Soret, P.-A., Magusto, J., Housset, C., & Gautheron, J. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm10010036 · Cited by 121
“Hence, fast food diet feeding is secondarily needed to trigger steatohepatitis and fibrosis in these mice [143,144].”
Background
Metadata
- Authors
- Jacobs, A., Warda, A., Verbeek, J., Cassiman, D., & Spincemaille, P.
- Venue
- Current Protocols in Mouse Biology
- Publisher
- Wiley
- Published
- 2016-06
- Volume
- 6
- Issue
- 2
- Pages
- 185-200
- ISSN
- 2161-2617 (ISSN-L)
- OpenAlex
- W2411199679
- Cited by
- 57
- References
- 17
- FWCI
- 6.27
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.